The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Addressing CAR-NK unknowns
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, highlights unanswered questions regarding the clinical utility of CAR-NK cells for the treatment of multiple myeloma. While CAR-NK appears to be a promising strategy that could be safer and faster than current CAR-T therapies, it is unclear whether cell migration and persistence are comparable. Investigations into these important questions are ongoing. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
